ArticleDiscover oncology2026
Institutional experience and pooled survival analysis of chemotherapy based multimodal management in poorly differentiated chordoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPoorly differentiated chordoma (PDC) is an exceptionally rare bone tumor with aggressive behavior and early recurrence. Evidence on the role and integration of chemotherapy remains limited. We aimed to share our institutional management experience and identify clinical prognostic factors in PDC.
methodsFive consecutive patients with axial PDC treated at our spinal tumor center (June 2021-June 2025) received surgery and anthracycline-ifosfamide (AI) chemotherapy. Neoadjuvant response was assessed by RECIST 1.1 and overall survival (OS) by Kaplan-Meier. We also reviewed histologically confirmed PDC cases reported in the literature with eligible treatment and outcome data, and compared OS by chemotherapy exposure and other factors using log-rank tests.
resultsThe mean age in our series was 21.4 years; all tumors were mobile-spine PDC with INI-1 loss and brachyury positivity. Neoadjuvant AI-based combination therapy achieved a partial response (PR) in one patient. Median progression-free survival was 13 months and median OS was 21 months. In the pooled cohort (n = 30), there was a female predominance. Prior recurrence was associated with inferior OS. In descriptive comparisons, patients receiving chemotherapy-based multimodality therapy had longer observed OS than those receiving local therapy without chemotherapy, including among recurrent cases. Whereas radiotherapy did not show a comparable survival benefit, this finding should be interpreted cautiously given the likelihood of substantial selection bias and the palliative role of RT in many recurrent cases.
conclusionsAI-based chemotherapy, particularly in the neoadjuvant setting, was feasible and showed preliminary antitumor signal in selected patients. However, the patient who achieved a partial response also received apatinib; thus, the specific contribution of AI chemotherapy cannot be isolated. In the pooled exploratory analysis, patients who received chemotherapy had a longer observed median OS than those receiving local therapy alone. However, due to the broad definition of chemotherapy and high risk of selection bias, this finding is presented as purely descriptive and hypothesis-generating, and does not imply a meaningful association between chemotherapy and improved OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.